

22 September 2017

Omni Innovation Executes Chinese Licence Agreement

EVE Investments provides for your information a copy of a release made by Eagle Health Holdings (ASX:EHH) today on completion of the Licence Agreement with EVE's portfolio company, Omni Innovation. Omni Innovation is a medical technology company focused on medical nutrition in which EVE has a ~40% interest.

About Omni Innovation

Omni Innovation creates unique and specialised medical food products that can be used by people with chronic and lifestyle diseases. Omni's products are independently validated and supervised by Omni's expert collaborator network to ensure that customers have safe, effective and clinically tested products that provide benefit with scientific backing.

About Eagle Health Holdings Limited

Eagle Health Holdings Limited (ASX: EHH) is a vertically integrated nutritional products business that aims to help people live healthier lives by developing, manufacturing, marketing and distributing a range of health food products and nutritional and dietary supplements under its own brand in China. The Company distributes its products through a broad range of channels, including pharmacies, health food stores, trading companies, supermarkets and online channels, covering 23 provinces and autonomous regions throughout China.

About EVE Investments

EVE Investments is an Australian Securities Exchange Listed Investment Company that invests in technology companies. With a preference for companies that have global scale, EVE is an investment partner that wants to help build ground breaking and enduring technology.

For more information, please visit www.eveinvestments.com.au and follow us on Twitter @EVEInvestments

For more information:

Ben Rohr
Investment Director
+61 8 6465 5500
benr@eveinvestments.com.au



ASX Announcement
22 September 2017

EAGLE HEALTH ENTERS MANUFACTURING, MARKETING & DISTRIBUTION LICENSE AGREEMENT WITH OMNI INNOVATION

Eagle Health Holdings Limited (ASX: EHH) (“Eagle Health” or “Company”) is pleased to announce that as part of its strategy to leverage efficacious, clean green Australian ingredients and brands into the China market, the Company has signed a Licensing Agreement with **Omni Innovation Pty Ltd (“Omni”)** to exclusively manufacture, market and distribute Omni’s clinically proven pre-meal shake product for Type 2 diabetes and Pre-Type 2 diabetes throughout mainland China through the Eagle Health’s extensive network of pharmacies, online and other retail outlets.

Eagle Health estimates that in 2018 there will be over 120 million men and women in China suffering from Type 2 diabetes growing to over 160 million by 2030. An aging and growing population and increasing obesity are the main drivers of this alarming trend that is particularly prevalent in urban Chinese locations.

Eagle Health’s strong pharmacy and supermarket distribution footprint in urban China means that the Company is well positioned to help Type 2 diabetes sufferers make the necessary lifestyle and diet changes with the support of their Healthcare Professional and this product.



Arie Nudel Managing Director Omni Innovation, Ian Brown Chairman Omni Innovation, Zhang Ming Wang CEO Eagle Health Holdings Ltd, Professor Michael Horowitz Professor of Medicine & Head Endocrine Unit Adelaide Medical School and Rodney Hannington Executive Director Eagle Health Holding Ltd at the signing of the Licensing Agreement.



Mr Zhang Mingwang, Managing Director of Eagle Health, said:

“We are honoured to be able to provide Type 2 diabetes sufferers in China such a world class and clinically validated solution to support them in their lifestyle intervention in order to manage this serious national health issue.

“We know that Chinese consumers and their Healthcare practitioners will recognise Omni’s clinical efficacy and the high quality product developed in Australia and now produced by the trusted Eagle Health Brand.”

The product will be sold in Pharmacies, On-line and Supermarkets in China at an affordable price to ensure maximum reach of sufferers.

About Omni Innovation

Omni Innovation creates unique and specialised medical nutrition products that can be used by people with chronic and lifestyle diseases. Omni's products are independently validated and supervised by Omni's expert collaborator network to ensure that customers have safe, effective and clinically tested products that provide benefit with scientific backing.

About Eagle Health Holdings Limited

Eagle Health Holdings Limited is a vertically integrated nutritional products business that aims to help people live healthier lives by developing, manufacturing, marketing and distributing a range of health food products and nutritional and dietary supplements under its own brand in China. The Company distributes its products through a broad range of channels, including pharmacies, health food stores, trading companies, supermarkets and online channels, covering 23 provinces and autonomous regions throughout China.

For more information visit: <http://www.eaglehealthltd.com/EN/index.aspx>

For further information please contact:

Rod North, Managing Director,
Bourse Communications Pty Ltd
T: +613 9510 8309, **M:** +61 408 670 706,
E: rod@boursecommunications.com.au

For personal use only